UBS AG Reiterates Buy Rating for AstraZeneca (AZN)
AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by analysts at UBS AG in a research report issued to clients and investors on Friday, AnalystRatingsNetwork.com reports. They currently have a GBX 4,150 ($68.20) target price on the stock. UBS AG’s target price points to a potential upside of 7.51% from the company’s current price.
Shares of AstraZeneca (LON:AZN) opened at 3859.9998 on Friday. AstraZeneca has a 1-year low of GBX 2895.00 and a 1-year high of GBX 3964.50. The stock has a 50-day moving average of GBX 3727.14 and a 200-day moving average of GBX 3387.81. The company’s market cap is £48.366 billion.
Other equities research analysts have also recently issued reports about the stock. Analysts at Societe Generale raised their price target on shares of AstraZeneca from GBX 3,030 ($49.79) to GBX 3,126 ($51.37) in a research note to investors on Friday. They now have a “sell” rating on the stock. Separately, analysts at Credit Suisse reiterated an “underperform” rating on shares of AstraZeneca in a research note to investors on Friday. They now have a GBX 4,000 ($65.74) price target on the stock. Finally, analysts at Liberum Capital reiterated a “buy” rating on shares of AstraZeneca in a research note to investors on Friday. They now have a GBX 4,600 ($75.60) price target on the stock. Ten equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and six have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of GBX 3,440.70 ($56.54).
AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.